A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 07 Jan 2019 According to an Idorsia Pharmaceuticals media release, first patient has been enrolled in this study.
- 21 Dec 2018 Planned End Date changed from 11 Jun 2019 to 15 Sep 2021.
- 21 Dec 2018 Planned primary completion date changed from 11 Jun 2019 to 17 May 2021.